Standout Papers

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial 2019 2026 2021 2023 360
  1. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial (2019)
    Robert D. McBane, Waldemar E. Wysokiński et al. Journal of Thrombosis and Haemostasis

Immediate Impact

35 standout
Sub-graph 1 of 14

Citing Papers

Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
2024 Standout
Glioma
2024 Standout
2 intermediate papers

Works of Usha Perepu being referenced

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial
2021
Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Usha Perepu 454 87 65 332 152 16 544
Ewa Wysokinska 376 149 59 230 72 34 642
Luciana Tamie Kato Morinaga 172 49 58 227 33 16 550
C. Grangé 186 97 84 128 40 28 540
T Südhoff 136 57 202 150 119 24 550
Siavash Piran 391 100 17 331 57 26 626
Nancy Amoroso 345 128 54 160 91 22 633
M S Elliot 262 278 93 93 106 21 515
Suzanne M. Bleker 406 90 36 251 134 21 503
Reina Valle 509 185 11 301 163 19 585
R.E.J. Roach 248 80 31 176 26 15 645

All Works

Loading papers...

Rankless by CCL
2026